Systemic study of pathogenic pathways and interrelationships underlying genes associated with Alzheimer's disease (AD) facilitates the identification of new targets for effective treatments. Recently available large-scale multiomics datasets provide opportunities to use computational approaches for such studies. Here, we devised a novel disease gene identification (digID) computational framework that consists of a semi-supervised deep learning classifier to predict AD-associated genes and a protein–protein interaction (PPI) network-based analysis to prioritize the importance of these predicted genes in AD. digID predicted 1,529 AD-associated genes and revealed potentially new AD molecular mechanisms and therapeutic targets including GNAI1 and GNB1, two G-protein subunits that regulate cell signaling, and KNG1, an upstream modulator of CDC42 small G-protein signaling and mediator of inflammation and candidate coregulator of amyloid precursor protein (APP). Analysis of mRNA expression validated their dysregulation in AD brains but further revealed the significant spatial patterns in different brain regions as well as among different subregions of the frontal cortex and hippocampi. Super-resolution STochastic Optical Reconstruction Microscopy (STORM) further demonstrated their subcellular colocalization and molecular interactions with APP in a transgenic mouse model of both sexes with AD-like mutations. These studies support the predictions made by digID while highlighting the importance of concurrent biological validation of computationally identified gene clusters as potential new AD therapeutic targets.

It may soon be possible to vaccinate ourselves against the diseases of old age, keeping our body and brain healthier for longer

Promising new vaccines are designed to be given to patients at risk of developing Alzheimer's disease. If they perform well in clinical trials, they have the potential to one day rid society of dementia

Title: Type 2 Diabetes May Have Link to Alzheimer's
Category: Health News
Created: 8/26/2010 10:43:00 AM
Last Editorial Review: 8/26/2010 10:43:52 AM

Title: Brain Scans Show Risk Factor for Alzheimer's
Category: Health News
Created: 8/25/2011 11:01:00 AM
Last Editorial Review: 8/25/2011 12:00:00 AM

Title: Alzheimer's Drug Shows Some Promise in Trials
Category: Health News
Created: 8/24/2012 2:05:00 PM
Last Editorial Review: 8/27/2012 12:00:00 AM

Title: Health Tip: Coping With Early-Onset Alzheimer's
Category: Health News
Created: 8/28/2012 8:05:00 AM
Last Editorial Review: 8/28/2012 12:00:00 AM

Title: Mental Skills Decline More Sharply for Women With Alzheimer's: Study
Category: Health News
Created: 8/29/2012 6:05:00 PM
Last Editorial Review: 8/30/2012 12:00:00 AM

Title: Discovery May Improve Diagnosis of Alzheimer's, Parkinson's
Category: Health News
Created: 8/29/2012 6:05:00 PM
Last Editorial Review: 8/30/2012 12:00:00 AM

Title: Health Tip: At Risk for Alzheimer's?
Category: Health News
Created: 8/30/2013 7:35:00 AM
Last Editorial Review: 8/30/2013 12:00:00 AM

Title: Women at Risk for Alzheimer's Face Critical 10-Year Window, Study Says
Category: Health News
Created: 8/28/2017 12:00:00 AM
Last Editorial Review: 8/29/2017 12:00:00 AM

Title: Your Sleep Patterns and Alzheimer's Risk
Category: Health News
Created: 8/24/2020 12:00:00 AM
Last Editorial Review: 8/25/2020 12:00:00 AM

Title: Rapid Loss of Smell May Be an Early Sign of Alzheimer's
Category: Health News
Created: 7/29/2022 12:00:00 AM
Last Editorial Review: 7/29/2022 12:00:00 AM

Title: Rural Americans With Early Alzheimer's Find It Tough to See Specialists
Category: Health News
Created: 8/9/2022 12:00:00 AM
Last Editorial Review: 8/9/2022 12:00:00 AM

Title: Menopause Linked With Higher Alzheimer's Risk
Category: Health News
Created: 6/30/2022 12:00:00 AM
Last Editorial Review: 6/30/2022 12:00:00 AM

Simplified methods of acquisition and quantification would facilitate the use of synaptic density imaging in multicenter and longitudinal studies of Alzheimer disease (AD). We validated a simplified tissue-to-reference ratio method using SUV ratios (SUVRs) for estimating synaptic density with [¹¹C]UCB-J PET. Methods: Participants included 31 older adults with AD and 16 with normal cognition. The distribution volume ratio (DVR) using simplified reference tissue model 2 was compared with SUVR at short scan windows using a whole-cerebellum reference region. Results: Synaptic density was reduced in AD participants using DVR or SUVR. SUVR using later scan windows (60–90 or 70–90 min) was minimally biased, with the strongest correlation with DVR. Effect sizes using SUVR at these late time windows were minimally reduced compared with effect sizes with DVR. Conclusion: A simplified tissue-to-reference method may be useful for multicenter and longitudinal studies seeking to measure synaptic density in AD.

Over 4 decades of research support the link between Alzheimer disease (AD) and somatostatin [somatotropin-releasing inhibitory factor (SRIF)]. SRIF and SRIF-expressing neurons play an essential role in brain function, modulating hippocampal activity and memory formation. Loss of SRIF and SRIF-expressing neurons in the brain rests at the center of a series of interdependent pathological events driven by amyloid-β peptide (Aβ), culminating in cognitive decline and dementia. The connection between the SRIF and AD further extends to the neuropsychiatric symptoms, seizure activity, and inflammation, whereas preclinical AD investigations show SRIF or SRIF receptor agonist administration capable of enhancing cognition. SRIF receptor subtype-4 activation in particular presents unique attributes, with the potential to mitigate learning and memory decline, reduce comorbid symptoms, and enhance enzymatic degradation of Aβ in the brain. Here, we review the links between SRIF and AD along with the therapeutic implications.

Promising new vaccines are designed to be given to patients at risk of developing Alzheimer's disease. If they perform well in clinical trials, they have the potential to one day rid society of dementia

Despite the limitations of Alzheimer's drugs like lecanemab, this new class of treatments and a group of experimental vaccines are paving the way to a world without dementia

Researchers have successfully induced a hibernation-like torpor state in Xenopus laevis tadpoles using donepezil (DNP), a drug FDA-approved for medlinkAlzheimer's/medlink treatment.

A new association between early-onset Alzheimer's disease and increased LDL cholesterol levels has been identified by Atlanta Veterans Affairs Medical Center and Emory University researchers.

Compared to other diabetes medications, semaglutide might offer added protection against Alzheimer's for type 2 diabetes patients.

In a mouse model of Alzheimer's disease, decreasing the methylation of a key messenger RNA was found to enhance migration of macrophages into the brain

Nitric oxide's role in brain disorders can be used in treating autism, Alzheimer's disease, and brain cancers.

New research has found that autism spectrum disorder (ASD) and Alzheimer's disease may share common molecular mechanisms. Professor Haitham Amal, head

Alzheimer's Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology

A novel, disease-modifying therapy or treatment for Alzheimer's disease that may involve a whole blood transfusion effectively reduces amyloid plaque

A team of researchers has identified how the APOE4 protein, a major genetic risk factor for Alzheimer's disease, can negatively impact brain health. They

Patients with Alzheimer's dementia having delirium suffer from a huge healthcare costs as per a study "One-year Medicare costs associated with delirium

While early detection of Alzheimer's disease is crucial for better outcomes, a report on Wednesday said that blood-based tests are emerging as valuable tools.

Produced by WIRED Brand Lab with Labcorp | One of the biggest challenges for people with Alzheimer’s Disease and their caregivers is the path to a correct diagnosis. Recent advancements in biomarker technology are about to change that by measuring neurodegeneration in the brain, differentiating Alzheimer’s from other forms of neurodegenerative disorders, and even producing a diagnosis years before symptoms appear. Dr. Marcia Eisenberg, Chief Scientific Officer at Labcorp, shares the development of these technologies and their implementation, physician and Professor of Neurology Dr. Marwan Sabbagh speaks to the impact of these advancements and Jamie Haendel shares her personal experience with the disease, as daughter and caregiver to Paula Haendel, a woman diagnosed with Alzheimer’s.

Alzheimer’s, a progressive form of dementia, may occur in middle age or in old age, and while a lot of research is on for drug treatments, none has been successful.

Researcher says the 'super fruit ' can have a real benefit in improving memory and cognitive function in some older adults

Such a probe can easily be fabricated into a strip-based kit that may enable on-site diagnosis

Study suggests activating PPAR receptor leads to increased cellular connections in hippocampus

An antibody called BAN2401 cleared amyloid-β proteins and slowed cognitive decline in people with mild Alzheimer’s disease

The aim of this consultation, held on 20-21 June 2013 in Oxford (UK), was to stimulate discussion at the highest possible level of expert engagement in setting out an agenda for OECD action to accelerate innovation for Alzheimer’s disease and dementia.

Although the causes of Alzheimer's disease are still unknown, it is clear that the disease commences with progressive amyloid deposition in the brains of affected persons between ten and fifteen years before the emergence of initial clinical symptoms such as memory loss. Researchers have now been able to show that Aducanumab, a human monoclonal antibody, selectively binds brain amyloid plaques, thus enabling microglial cells to remove the plaques. A one-year treatment with the antibody, as part of a phase Ib study, resulted in almost complete clearance of the brain amyloid plaques in the study group patients. The results, which were realized by researchers at UZH together with the biotech company "Biogen" and the UZH spin-off "Neurimmune," have been published in the renowned science journal "Nature."

read more

Wanted: Test scores from 1 million people as web-based research project aims to learn more about the region of DNA that determines how the brain works.

Marilu Henner and others stage reading 'Surviving Grace,' a play about Alzheimer's.

Could Alzheimer's really just be another form of diabetes, caused by eating too much junk food?

New German study finds that people taking this type of generic diabetes medication were less likely to develop diabetes.